Answers are grounded in this paper and cite their sources.
Diabetic retinopathy (DR) is a diabetes-induced microangiopathy. MicroRNAs (miRNAs), given their stability and disease correlation, hold promise as diagnostic biomarkers. To explore the clinical value of miR-337-5p in DR, as well as its functions and regulatory mechanisms in this condition. A total of 132 non-diabetic retinopathy (NDR) and 140 DR patients were included. RT‑qPCR was used to determine miR‑337‑5p and WNK1 levels. The diagnostic efficacy and predictive value of miR-337-5p for DR were evaluated, and the correlation between it and disease progression was analyzed. CCK‑8 and Transwell assays evaluated the proliferation and migration abilities of Human Retinal Microvascular Endothelial cells (hRMECs). ELISA measured inflammatory factors. Dual‑luciferase reporter and rescue assays demonstrated the regulatory interaction between miR‑337‑5p and WNK1. The level of miR-337-5p in DR patients was reduced compared to NDR, and it further decreased in proliferative diabetic retinopathy (PDR) compared to NPDR. The level of miR-337-5p has clinical value in differentiating NDR/DR and NPDR/PDR, and it was an independent protective factor for DR. High glucose (HG) induction can reduce the level of miR-337-5p in hRMECs, while increasing cell proliferation, migration, and inflammatory levels; overexpression of miR-337-5p can reverse these effects, and inhibiting its expression will exacerbate the effects. And miR-337-5p exerts its effect by targeting and binding to WNK1. The level of miR-337-5p has important clinical significance for the diagnosis and progression assessment of DR. MiR-337-5p can inhibit the damage caused by HG to hRMECs by targeting WNK1, potentially contributing to DR pathogenesis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: